Reply #5: From the Northfield link: [View All]

[acmavm]

<snip>
This is the first U.S. trial of a hemoglobin-based oxygen-carrying resuscitative fluid in which treatment begins in the prehospital setting. The trial will be conducted in approximately 25-30 Level 1 trauma centers throughout the U.S. 720 patients will be enrolled in the trial.

Treatment begins at the scene of injury, continues in the ambulance during transport, and for up to 12 hours post-injury or 6 units in the hospital. The trial is designed to evaluate PolyHeme® compared to the current standard of care, namely salt water in the ambulance followed in the hospital by donated blood, when needed. The primary endpoint is survival at 30 days.
<snip>